Alisertib (MLN8237)

Catalog No.S1133

Alisertib (MLN8237) Chemical Structure

Molecular Weight(MW): 518.92

Alisertib (MLN8237) is a selective Aurora A inhibitor with IC50 of 1.2 nM in a cell-free assay. It has >200-fold higher selectivity for Aurora A than Aurora B. Phase 3.

Size Price Stock Quantity  
In DMSO USD 168 In stock
USD 120 In stock
USD 210 In stock
USD 670 In stock

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 46 Publications

10 Customer Reviews

  • Inhibition of Aurka kinase activity by MLN8237 impairs expression of pluripotency genes in CCE cells as measured by qRT-PCR. All values shown are mean ?SEM for n=3. The level of phosphorylated H3(S10) (p-H3(S10)), an Aurka phosphorylation target site, is decreased in MLN8237-treated samples.

    Cell Stem Cell 2012 11, 179-94. Alisertib (MLN8237) purchased from Selleck.

    Recruitment of clathrin to the mitotic spindle is controlled by phosphorylation of TACC3 by Aurora-A kinase. Representative micrographs of HEK293 cells incubated with 0.3 μM MLN8237 for 40 min. Cells were fixed and stained as indicated.

    EMBO J 2012 30, 906-19. Alisertib (MLN8237) purchased from Selleck.

  • Aurora A inhibition rescues the PPP6C depletion phenotype. (A) HeLa cells transfected for 48 h with control and PPP6C si08 duplexes were treated with 10 or 20 nM MLN8237 or a solvent control for 15 min before lysis in phosphatase inhibitor containing buffer or fixation. Total lysates were analyzed by Western blotting. The red and black lines indicate the hosphorylated and nonphosphorylated forms of Aurora A. Fixed cells were stained using DAPI to detect DNA and antibodies to α-tubulin and Aurora A pT288. The intensity of pT288 staining was integrated using ImageJ over the spindle region defined by TPX2 staining and is plotted in the bar graph ( n = 4). Arrowheads indicate micronuclei. Bar, 5 µm. (B) HeLa cells transfected for 48 h with control and PPP6C si08 duplexes were treated with 10 nM MLN8237 or a solvent control for 24 h before fixation and staining with DAPI to detect DNA.

    J Cell Biol 2010 191, 1315-32. Alisertib (MLN8237) purchased from Selleck.

    NUSAP mitotic phosphorylation at Ser 240 correlates with Aurora A activity. Protein samples of FLAG-NUSAP immunoprecipitated from I, M and MtMLN or with MtZM were analysed using LC-MS/MS, focusing on the predicted phosphorylated residue Ser 240. The histograms (A, B) show the calculated ratios based on peptides carrying the phosphorylated Ser 240 compared with all matched peptides containing this residue.

     

     

    EMBO reports 2010 11, 977-984. Alisertib (MLN8237) purchased from Selleck.

  • Tissue levels of 53BP1, a-tubulin, IkB-a and IL-6 in an Hs294T xenograft treated with MLN8237 or vehicle control were visualized by immunofluorescence co-staining with DAPI. Representative micrographs are shown from triplicate experiments.

    EMBO Mol Med 2013 5(1), 149-66. Alisertib (MLN8237) purchased from Selleck.

    Alisertib inhibits AURKA and AURKB in a concentration-dependent manner. (a) Alisertib induces G 2 /M delay or genome reduplication. HeLa cells were exposed to buffer or the indicated concentrations of Alisertib. After 24 h, the cells were harvested and analyzed with flow cytometry. The positions of 2N, 4N and 8N DNA contents are indicated. (b) Alisertib delays mitotic exit or induces slippage. HeLa cells stably expressing histone H2B-GFP were exposed to buffer or the indicated concentrations of Alisertib. Individual cells were then tracked for 24 h with time-lapse microscopy. Each horizontal bar represents one cell (n ¼ 50). Key: light gray ¼ interphase; black ¼ mitosis (from DNA condensation to anaphase or mitotic slippage); dark gray ¼ interphase after mitotic slippage; truncated bars ¼ cell death. (c) Different concentrations of Alisertib are involved in delaying mitotic exit and inducing slippage. Live-cell imaging of cells treated with Alisertib was described in panel (b). The duration of mitosis (mean±90% confidence interval) and the percentage of cells that underwent mitotic slippage during the imaging period was quantified. (d) Alisertib promotes apoptosis in a concentration-dependent manner. HeLa cells were incubated with the indicated concentrations of Alisertib for 48 h. The cells were then harvested and analyzed with flow cytometry. (e) Concentration-dependent cytotoxicity of Alisertib. HeLa cells were cultured in the presence of the indicated concentrations of Alisertib for 48 h. The number of live and dead cells was analyzed with trypan blue exclusion assay. (f) Concentration-dependent suppression of long-term survival by Alisertib. HeLa cells were seeded on 60-mm culture plates and grown in the presence of 250 n M or 1 m M of Alisertib. After 24 h, the cells were washed gently and propagated in normal medium for another 10–12 days. Colonies were fixed and stained with crystal violet solution (examples of the plates are shown). Average±s.d. from three independent experiments. (g) Both AURKA and AURKB are inhibited by Alisertib.Mitotic HeLa cells were obtained by exposure to nocodazole for 16 h followed by mechanical shake off. The cells were incubated with the indicated concentrations of Alisertib for 2 h. Lysates were then prepared and activated phospho-AURKAThr288 and AURKBThr232were detected with immunoblotting. The asterisk indicates the position of an AURKB-like protein (the same throughout this study). Uniform loading was confirmed by immunoblotting for actin. In this assay, nocodazole and MG132 (a proteasome inhibitor) were added to prevent the cells from exiting mitosis. Accordingly, the total AURKA and AURKB levels remained constant throughout the experiment. (h) Alisertib prevents activation of AURKA and AURKB. HeLa cells were incubated with the indicated concentrations of Alisertib for 8 h. Nocodazole was then added for another 6 h to trap cells that entered mitosis. Lysates were prepared and analyzed with immunoblotting. Actin analysis was included to assess loading and transfer.

    Oncogene 2014 33, 3550-60. Alisertib (MLN8237) purchased from Selleck.

  • Inhibition of Aurora A (12.5 nM) by MLN8054 or MLN8237 was assessed in duplicate radiometric assays containing 100 μM [γ-32P] ATP and quantified by p81 phosphocellulose assay and scintillation counting. Kinase activity is reported as a percentage of control calculated from duplicate incubations containing 2.5% (v/v) DMSO. IC50 values represent the mean ±SEM calculated from two independent experiments.

     

     

    ACS Chem Biol 2010 5, 563-576. Alisertib (MLN8237) purchased from Selleck.

    The effects of T217D and T217N Aurora A mutations were directly compared to WT Aurora A-expressing cells. Each well was treated with either DMSO or 500 nM MLN8054 (E), or 30 nM MLN8237 (F) on day one of the experiment and cells were cultured for 8 days, at which point they were fixed. For all colony assays, an area encompassing >90 % of the colonies per dish is shown. Similar results were seen in two independent duplicate experiments.

    ACS Chem Biol 2010 5, 563-576. Alisertib (MLN8237) purchased from Selleck.

  • C, Fry depletion decreases the level of Thr-210 phosphorylation of Plk1 on spindle poles. HeLa cells transfected with siRNAs were cultured in growth medium for 12 h and in thymidine-containing medium for 36 h. They were then released from thymidine arrest for 12 h before being fixed and stained with anti-Plk1 pT210 ( green) and anti-pericentrin (red) antibodies. DNA was stained with TO-PRO-3 ( blue ). For Aurora A inhibition, after release from thymidine block for 10 h, HeLa cells transfected with control siRNA were incubated for2h in medium containing MLN8237 (100 nM) and MG132 (10 μM). Magnified images of the white boxes are also shown. Scale bar ,5 μm.

    J Biol Chem 2012 287, 27670-81. Alisertib (MLN8237) purchased from Selleck.

    Eg5 inhibition counteracts the induction of spindle pole fragmentation by Aurora-A inactivation. The protocol to inhibit Aurora-A by MLN8237 in cells progressing towards mitosis is depicted (time intervals not represented to scale). Control cultures were treated with solvent (DMSO) in the same time window. When indicated, MON was added 1 hour before harvesting. Note the absence of active phosphorylated (pThr288) Aurora-A (in red in IF panels) in cells treated with MLN8237. Upper histograms represent the percentage of all spindle and MT abnormalities in control and MLN8237-treated cultures (200 counted PM/M per condition in 2 experiments); the grey fraction of the histograms represents mitoses with spindle extrapoles, while other defects (monopolar or disorganised spindles, few and short MTs) are in white. Lower histograms and IF panels show that concomitant Eg5 inhibition by MON prevents MLN8237-induced spindle pole fragmentation (note the failure of centrosome migration reflecting Eg5 inactivation in lower IF panels). 200 PM/M per condition were counted in 2 experiments. Error bars represent s.d. **: p < 0.001, χ2 test. Red asterisks indicate significant differences with respect to DMSO controls, and black asterisks significant differences between Aurora-Ai mitoses with active or inactive Eg5. Scale bar: 10 μm

    Mol Cancer 2011 10, 131. Alisertib (MLN8237) purchased from Selleck.

Purity & Quality Control

Choose Selective Aurora Kinase Inhibitors

Click to view more

Notes:

2. For more details, such as half maximal inhibitory concentrations (IC50s) and working concentrations of each inhibitor, please click on the link of the inhibitor of interest.
3. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation.
4. Orange "√" refers to compounds which do inhibitory effects on the related isoform, but without specific value.

Biological Activity

Description Alisertib (MLN8237) is a selective Aurora A inhibitor with IC50 of 1.2 nM in a cell-free assay. It has >200-fold higher selectivity for Aurora A than Aurora B. Phase 3.
Features First orally available inhibitor of Aurora A.
Targets
Aurora A [1]
(Cell-free assay)
Aurora B [1]
(Cell-free assay)
1.2 nM 396.5 nM
In vitro

MLN8237 shows >200-fold higher selectivity for Aurora A than the structurally related Aurora B with an IC50 of 396.5 nM, and does not have any significant activity against 205 other kinases. [1] MLN8237 (0.5 μM) treatment inhibits the phosphorylation of Aurora A in MM1.S and OPM1 cells, without affecting the Aurora B mediated histone H3 phosphorylation. MLN8237 significantly inhibits cell proliferation in multiple myeloma (MM) cell lines with IC50 values of 0.003-1.71 μM. MLN8237 displays more potent anti-proliferation activity against primary MM cells and MM cell lines in the presence of BM stroma cells, as well as IL-6 and IGF-1 than against MM cells alone. MLN8237 (0.5 μM) induces 2- to 6-fold increase in G2/M phase in primary MM cells and cell lines, as well as significant apoptosis and senescence, involving the up-regulation of p53, p21 and p27, as well as PARP, caspase 3, and caspase 9 cleavage. In addition, MLN8237 shows strong synergistic anti-MM effect with dexamethasone, as well as additive effect with doxorubicin and bortezomib. [2] MLN8237 (0.5 μM) treatment causes the inhibition of colony formation of FLO-1, OE19, and OE33 esophageal adenocarinoma cell lines, and induces a significant increase in the percentage of polyploid cells, and subsequently an increase in the percentage of cells in the sub-G1 phase, which can be further enhanced in combination with cisplatin (2.5 μM), involving the higher induction of TAp73β, PUMA, NOXA, cleaved caspase-3, and cleaved PARP as compared with a single-agent treatment. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HCT116 MmK5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3OyZVAvPSEQvF2= M{\5bFczKGh? M1fyfGROW09? Mof5TWM2OD1yLkC0JO69VQ>? M373[VI3OTN4Nki0
LS174T NUntOVQ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUnMbJpsOC53IN88US=> NIjaPXg4OiCq MXzEUXNQ Ml\vTWM2OD1yLkC1JO69VQ>? NGTOZ2wzPjF|Nk[4OC=>
T84 M4qxR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVzEVWRTOC53IN88US=> NXXGUYdKPzJiaB?= NHG5eo1FVVOR M1zPUGlEPTB;MD6wPUDPxE1? MkmzNlYyOzZ4OES=
LS180 NGizUm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M37TfVAvPSEQvF2= MYC3NkBp MUXEUXNQ M4GwdWlEPTB;MTFOwG0> M2nFZVI3OTN4Nki0
SW948 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF\v[5YxNjVizszN NYnYN4g3PzJiaB?= NIHTeXVFVVOR MYfJR|UxRTFizszN NEflWY8zPjF|Nk[4OC=>
HCT15 MmnMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYjIPJNxOC53IN88US=> M2fOSFczKGh? M1iwWWROW09? M3zGdmlEPTB:MD60JO69VQ>? NX3FPZE6OjZzM{[2PFQ>
DLD-1 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFXt[YoxNjVizszN MWe3NkBp MWPEUXNQ NIrMTXVKSzVyPECuPEDPxE1? MoTNNlYyOzZ4OES=
MIP-101 M1LyZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml3ONE42KM7:TR?= NUf4Uo1pPzJiaB?= MWTEUXNQ MlTuTWM2OD1zIN88US=> NIXKWVIzPjF|Nk[4OC=>
SNU1544 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUGwMlUh|ryP NYnpeplZPzJiaB?= MULEUXNQ M3PVTmlEPTB;MTFOwG0> NF\OSmkzPjF|Nk[4OC=>
OCI-Ly10 NWDwUJJkS3m2b4TvfIlkKEG|c3H5 MUK3NkBp MWnEUXNQ NWDUe|dTUUN3ME2wMlA2QCEQvF2= MUWyOVg4QDN|MR?=
SU-DHL2 MX3DfZRwfG:6aXOgRZN{[Xl? NW\R[2xVPzJiaB?= MXzEUXNQ NVPPOIxkUUN3ME2wMlAyKM7:TR?= M{n6[lI2QDd6M{Ox
OCI-LY7 M33KU2N6fG:2b4jpZ{BCe3OjeR?= M{\pVlczKGh? NILuSVBFVVOR MUHJR|UxRTBwMEixJO69VQ>? NETCSo4zPTh5OEOzNS=>
SU-DHL6 NX7EdWFGS3m2b4TvfIlkKEG|c3H5 NGm3d204OiCq Mki3SG1UVw>? MlvZTWM2OD1yLkS4NkDPxE1? NXHuZlB[OjV6N{izN|E>
Jeko-1 MlfMR5l1d3SxeHnjJGF{e2G7 M4nsVlczKGh? NVfVcGh3TE2VTx?= M4LafWlEPTB;MD6wNlkh|ryP M3vWXVI2QDd6M{Ox
JVM-2 NIr5RZZEgXSxdH;4bYMhSXO|YYm= MlTMO|IhcA>? M1rU[GROW09? MnHyTWM2OD1yLkCxJO69VQ>? Mk[wNlU5Pzh|M{G=
Rec-1 M2P6fWN6fG:2b4jpZ{BCe3OjeR?= M3\2XlczKGh? NI\nSHVFVVOR MkHHTWM2OD1yLkC4O{DPxE1? NGX0dZAzPTh5OEOzNS=>
Z-138 M4jBV2N6fG:2b4jpZ{BCe3OjeR?= MWO3NkBp NV;RVpNWTE2VTx?= MYjJR|UxRTBwMEGzJO69VQ>? M374fVI2QDd6M{Ox
H9 NITCcWlEgXSxdH;4bYMhSXO|YYm= NGT1Vm04OiCq NHvRTFFFVVOR MVLJR|UxRTBwNjFOwG0> NFzBWHUzPTh5OEOzNS=>
HH MnvaR5l1d3SxeHnjJGF{e2G7 NHHuR2U4OiCq M3ewR2ROW09? NF3FWXpKSzVyPUCuO{DPxE1? MW[yOVg4QDN|MR?=
DND41 NWDwSolGS3m2b4TvfIlkKEG|c3H5 MYW3NkBp M{LHOmROW09? M3LtfWlEPTB;MD6xJO69VQ>? M3jXdVI2QDd6M{Ox
CCL119 MmHIR5l1d3SxeHnjJGF{e2G7 NXuy[2VvPzJiaB?= NETiXZZFVVOR MlLZTWM2OD1yLkC2NkDPxE1? MUSyOVg4QDN|MR?=
J.Cam 1.6 M2DOPGN6fG:2b4jpZ{BCe3OjeR?= M2jSN|czKGh? M1KydmROW09? M4L2fWlEPTB;MD6xNFUh|ryP NVHtcVdQOjV6N{izN|E>
Sup-T1 M3;IemN6fG:2b4jpZ{BCe3OjeR?= MojZO|IhcA>? NFrrXYNFVVOR NWDrPWs2UUN3ME2yMlE1OiEQvF2= NV3T[ItNOjV6N{izN|E>
Tib 152 NVHlT|JKS3m2b4TvfIlkKEG|c3H5 MmK0O|IhcA>? NYr2U4RLTE2VTx?= NV;IS4tvUUN3ME2wMlgh|ryP NWHuSVR3OjV6N{izN|E>
MCF7 NHy5fWZHfW6ldHnvckBCe3OjeR?= NFzqVok2KM7:TR?= M{HnblI1KGh? MoL2SG1UVw>? NFPyXpJKdmS3Y3XzJGczN01iYYLy[ZN1 NHXtO2UzPTh|NESwNS=>
MDA-MB-231 MUDGeY5kfGmxbjDBd5NigQ>? M1XnPVUh|ryP NUjzcJg6OjRiaB?= MmD3SG1UVw>? NGPLRYhKdmS3Y3XzJGc{N01iYYLy[ZN1 M4O2ZlI2QDN2NECx
MCF7 MUDGeY5kfGmxbjDBd5NigQ>? NIn3TGY2KM7:TR?= MkTlNlQhcA>? M2DwN2ROW09? NEXHT2NF\WO{ZXHz[ZMhfGinIHX4dJJme3Orb36gcIV3\Wxib3[gR2RMOS:FRFOy NEf6OmEzPTh|NESwNS=>
MCF7 M1HwWGZ2dmO2aX;uJGF{e2G7 NIXyN5Y2KM7:TR?= NVnUNmU{OjRiaB?= NFvvW|hFVVOR MXPE[YNz\WG|ZYOgeIhmKGW6cILld5Nqd25ibHX2[Ywhd2ZiQ1TLNi=> NF;HRlIzPTh|NESwNS=>
MCF7 NXXyZ3Y3TnWwY4Tpc44hSXO|YYm= M1jUblUh|ryP M3\PPFI1KGh? NFP2eIZFVVOR M3ziSWRm[3KnYYPld{B1cGViZYjwdoV{e2mxbjDs[ZZmdCCxZjDjfYNtcW5iQkG= M4\nZlI2QDN2NECx
MCF7 NWO5ZnN5TnWwY4Tpc44hSXO|YYm= NW\KNWJ2PSEQvF2= NVvrVJkyOjRiaB?= NHnofGFFVVOR M3T3b2lv[3KnYYPld{B1cGViZYjwdoV{e2mxbjDs[ZZmdCCxZjDwNlEhX2GoMT;DbZAy M4PFe|I2QDN2NECx
MCF7 Mlf4SpVv[3Srb36gRZN{[Xl? NFLqVZg2KM7:TR?= MVWyOEBp M3LXWGROW09? NFLKT5lKdmO{ZXHz[ZMhfGinIHX4dJJme3Orb36gcIV3\Wxib3[gdFI4KEurcEG= NFv6Z3EzPTh|NESwNS=>
MDA-MB-231 M362eGZ2dmO2aX;uJGF{e2G7 NWfIRWFzPSEQvF2= NF3DU3IzPCCq Mo\USG1UVw>? MYHE[YNz\WG|ZYOgeIhmKGW6cILld5Nqd25ibHX2[Ywhd2ZiQ1TLNU9ETEN{ M3fqe|I2QDN2NECx
MDA-MB-231 MVLGeY5kfGmxbjDBd5NigQ>? NIXkW4QyKM7:TR?= NWHwUnQ2OjRiaB?= NUDnSVRLTE2VTx?= NFf1PXVKdmO{ZXHz[ZMhfGinIHX4dJJme3Orb36gcIV3\Wxib3[gR2RMOg>? MmC1NlU5OzR2MEG=
MDA-MB-231 M{P3[GZ2dmO2aX;uJGF{e2G7 MnvuOUDPxE1? M{XyT|I1KGh? NFuzO5lFVVOR M3TPemRm[3KnYYPld{B1cGViZYjwdoV{e2mxbjDs[ZZmdCCxZjDjfYNtcW5iQkG= M1H5NlI2QDN2NECx
MDA-MB-231 MX\GeY5kfGmxbjDBd5NigQ>? MlTzOUDPxE1? MYmyOEBp NUizdVFtTE2VTx?= NHXoR5dKdmO{ZXHz[ZMhfGinIHX4dJJme3Orb36gcIV3\Wxib3[gdFIyKFejZkGvR4lxOQ>? M4XH[lI2QDN2NECx
MDA-MB-231 NELaSmRHfW6ldHnvckBCe3OjeR?= NEDOclU2KM7:TR?= M3;r[FI1KGh? NIHhPYpFVVOR M4XPPWlv[3KnYYPld{B1cGViZYjwdoV{e2mxbjDs[ZZmdCCxZjDwNlchU2myMR?= NHr0bZAzPTh|NESwNS=>
MDA-MB-231 NWCxNollTnWwY4Tpc44hSXO|YYm= NFjOTGo2KM7:TR?= NYTPT25TOjRiaB?= M3XxbWROW09? NFLvd|dKdmO{ZXHz[ZMhfGinIHX4dJJme3Orb36gcIV3\Wxib3[gdFU{ NUDn[VVNOjV6M{S0NFE>
MCF7 MmjoRZBweHSxc3nzJGF{e2G7 M33XV|Uh|ryP M4jkW|I1KGh? NHLNXZNFVVOR MXnJcoR2[2W|IHHwc5B1d3SrYzDk[YF1cA>? Mmj1NlU5OzR2MEG=
MDA-MB-231 MmjDRZBweHSxc3nzJGF{e2G7 NXq1PYlvPSEQvF2= MnTHNlQhcA>? NFPUZ29FVVOR MYTJcoR2[2W|IHHwc5B1d3SrYzDk[YF1cA>? MXyyOVg{PDRyMR?=
MCF7 NWHxW29oTnWwY4Tpc44hSXO|YYm= NUS3fHZ{OSEQvF2= M1S5R|czKGh? NW\mR3I3TE2VTx?= M33lNmlv\HWlZYOgZZV1d3CqYXfpZ{Bl\WG2aB?= NVPpXodmOjV6M{S0NFE>
MDA-MB-231 MX\GeY5kfGmxbjDBd5NigQ>? MX:xJO69VQ>? MoLRO|IhcA>? MkHFSG1UVw>? M2m2S2lv\HWlZYOgZZV1d3CqYXfpZ{Bl\WG2aB?= NV;abnFWOjV6M{S0NFE>
U-2 OS MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1nPW|UxKM7:TR?= MkTLNlQhcA>? MVvEUXNQ MX7JR|UxRTF4Lk[g{txO NIfBZ5MzPTd7MkixNS=>
MG-63 M1;STWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUS1NEDPxE1? NFHvTWUzPCCq M171Z2ROW09? MWHJR|UxRTlwNTFOwG0> NICxfoozPTd7MkixNS=>
U-2 OS MkLLRZBweHSxc3nzJGF{e2G7 MkezOUDPxE1? MojyNlQhcA>? M1fLTmROW09? MVPJcoR2[2W|IHHwc5B1d3SrYzDj[YxtKGSnYYTo NFywdGwzPTd7MkixNS=>
MG-63 MXLBdI9xfG:|aYOgRZN{[Xl? NYnVfIp1PSEQvF2= NFrIVmkzPCCq MnrTSG1UVw>? NVPXOG5wUW6mdXPld{BieG:ydH;0bYMh[2WubDDk[YF1cA>? MUeyOVc6OjhzMR?=
U-2 OS NELqV3ZHfW6ldHnvckBCe3OjeR?= M4jJSlUh|ryP NFqxRmkzPCCq MWPEUXNQ NYi2NVhYWHKxbX;0[ZMh[XW2b4DoZYdq[yClZXzsJIRm[XSq NXnodXdxOjV5OUK4NVE>
MG-63 MoPXSpVv[3Srb36gRZN{[Xl? NGT2d4E2KM7:TR?= M{nVUlI1KGh? NVP6NVJLTE2VTx?= MYPQdo9ud3SnczDheZRweGijZ3njJINmdGxiZHXheIg> NH7nc3AzPTd7MkixNS=>
PANC-1 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVXTPYg{PTBizszN NH3EXJUzPCCq MVfEUXNQ NV\iZ3A6UUN3ME23MlEh|ryP NF\lcFczPTZ|MkKyOS=>
BxPC-3 NXrleHE{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrzUno2OCEQvF2= MYSyOEBp M{G5Z2ROW09? M4\EZmlEPTB;Nj64JO69VQ>? NIjIbXQzPTZ|MkKyOS=>
PANC-1 MmDuSpVv[3Srb36gRZN{[Xl? M4rGRlUh|ryP M17pZ|I1KGh? NU\ZbI1mTE2VTx?= NHTSZ5FKdmS3Y3XzJINmdGxiY4njcIUh[XK{ZYP0JIlvKEd{L12gdIhie2V? NIW1dHMzPTZ|MkKyOS=>
BxPC-3 NYj5[nVNTnWwY4Tpc44hSXO|YYm= M3z3OFUh|ryP Mn24NlQhcA>? NYrNe3JoTE2VTx?= NVruXGlPUW6mdXPld{Bk\WyuIHP5Z4xmKGG{cnXzeEBqdiCJMj;NJJBp[XOn MnjFNlU3OzJ{MkW=
PANC-1 NHjxWoxHfW6ldHnvckBCe3OjeR?= M2fpUlUh|ryP M{iyRVI1KGh? M3X3OWROW09? MXvJcoR2[2W|IHH1eI9xcGGpaXOgZ4VtdCCmZXH0bC=> Mm\XNlU3OzJ{MkW=
BxPC-3 M1\MSGZ2dmO2aX;uJGF{e2G7 M{\LS|Uh|ryP M3XGU|I1KGh? MUTEUXNQ NV74b4VqUW6mdXPld{BifXSxcHjh[4lkKGOnbHyg[IVifGh? M1Txc|I2PjN{MkK1
SKOV3 NXvrNXFGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX30cVZUOTByIN88US=> MWGyOEBp M{P1[mROW09? NELSSFVKSzVyPUKwMlQ5KM7:TR?= M2jrRlI2PjJ2N{Ww
OVCAR4 M2PZS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUH4bllHOTByIN88US=> MUiyOEBp MYXEUXNQ NETRNlNKSzVyPUKyMlE{KM7:TR?= Mn3INlU3OjR5NUC=
SKOV3 NXr3fGg6TnWwY4Tpc44hSXO|YYm= NUS0W5c4PSEQvF2= MYm3NkBp M3nDVWROW09? NFvPXWtKdmS3Y3XzJGczN01iYYLy[ZN1 NHzxcJozPTZ{NEe1NC=>
OVCAR4 Moi2SpVv[3Srb36gRZN{[Xl? NGji[5U2KM7:TR?= MXu3NkBp M13CVWROW09? NWDjRW94UW6mdXPld{BIOi:PIHHydoV{fA>? NWPoTWFMOjV4MkS3OVA>
SKOV3 MWjBdI9xfG:|aYOgRZN{[Xl? NV;zOIZNPSEQvF2= M{n2e|I1KGh? MV;EUXNQ NXP2UVl5UW6mdXPld{BieG:ydH;zbZM> NX6xc5VqOjV4MkS3OVA>
OVCAR4 M1fufGFxd3C2b4Ppd{BCe3OjeR?= M2DX[FUh|ryP MW[yOEBp Ml[1SG1UVw>? MWLJcoR2[2W|IHHwc5B1d3Orcx?= MYSyOVYzPDd3MB?=
AGS MnH4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF3oWmEzPSEQvF2= MViyOEBp MX3EUXNQ NWTyb|NwUUN3ME2xPU4xQSEQvF2= M1HxN|I2PjB7OUKz
NCI-N78 NIr6Z3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUSyOUDPxE1? M4XHOVI1KGh? Ml;zSG1UVw>? M3HlVGlEPTB;Mk[uN|Mh|ryP MVyyOVYxQTl{Mx?=
AGS NH\CbIFCeG:ydH;zbZMhSXO|YYm= NECzO2o2KM7:TR?= NYDC[IhXOjRiaB?= NX73[IViTE2VTx?= MVfJcoR2[2W|IHHwc5B1d3Orcx?= NXfNToRFOjV4MEm5NlM>
NCI-N78 MWXBdI9xfG:|aYOgRZN{[Xl? MXe1JO69VQ>? M2jXOFI1KGh? NXXHZ4RjTE2VTx?= M3\xe2lv\HWlZYOgZZBweHSxc3nz NE\Fc5kzPTZyOUmyNy=>
AGS MnnjSpVv[3Srb36gRZN{[Xl? M4PoUlUh|ryP NG\od5QzPCCq MV3EUXNQ M4DyXWlv\HWlZYOgeIhmKGG3dH;wbIFogQ>? NUDUZll2OjV4MEm5NlM>
NCI-N78 M{fHd2Z2dmO2aX;uJGF{e2G7 NVn5bpBCPSEQvF2= M1raNlI1KGh? M3fibmROW09? MkfRTY5lfWOnczD0bIUh[XW2b4DoZYd6 NYnzXJQxOjV4MEm5NlM>
HSC-3 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGe4NVEyKM7:TR?= NIG5Zpk1QCCq M1HLWGlEPTB;MD61OEDPxE1? NIfnZVMzPTN4NkG0Ny=>
GB30 Mo\kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1fIPFEh|ryP Ml3tO{Bl M13HTWROW09? MX3JR|UxRTBwMEGxJO69VQ>? MmfSNlUyODZ2Mki=
GB9 Mkn1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHW2T2gyKM7:TR?= MUK3JIQ> NUW1UIJGTE2VTx?= M2fZdWlEPTB;MD6wNlQh|ryP MX[yOVExPjR{OB?=
GB169 NGnqWHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWj6Z|VWOSEQvF2= NH\Ve3k4KGR? NID0eZhFVVOR NWn5VnpHUUN3ME2wMlA{OiEQvF2= MYOyOVExPjR{OB?=
T24 MV3GeY5kfGmxbjDBd5NigQ>? MYqxJO69VQ>? M1XydVQ5KGh? MlHVSG1UVw>? MVXJcoR2[2W|IHPlcIwh[3mlbHWgZZJz\XO2 NFjjeVIzOzRyM{[zNy=>
RT4 MkTLSpVv[3Srb36gRZN{[Xl? M1LnW|Eh|ryP MmjYOFghcA>? Ml7tSG1UVw>? NWDTW2oyUW6mdXPld{Bk\WyuIHP5Z4xmKGG{cnXzeC=> NYrrbHI3OjN2MEO2N|M>
UM-UC-3 MVzGeY5kfGmxbjDBd5NigQ>? NEHnem4yKM7:TR?= MXG0PEBp MoPFSG1UVw>? M1PRemlv\HWlZYOgZ4VtdCCleXPs[UBienKnc4S= MWCyN|QxOzZ|Mx?=
T24 NF\JcmhCeG:ydH;zbZMhSXO|YYm= MoPuN{4yPiEQvF2= M4jESFk3KGh? MkjySG1UVw>? MlX3TWM2OD1yLkCzNFYh|ryP MYWyN|QxOzZ|Mx?=
RT4 NVzlV2FvSXCxcITvd4l{KEG|c3H5 MWqzMlE3KM7:TR?= Mk[2PVYhcA>? M3HpPWROW09? MlT6TWM2OD1yLkGxPVgh|ryP MoWyNlM1ODN4M{O=
UM-UC-3 NX;TRo5VSXCxcITvd4l{KEG|c3H5 MnzkN{4yPiEQvF2= NF\UOYE6PiCq MVTEUXNQ MmPSTWM2OD1yLkC0OFkh|ryP MXKyN|QxOzZ|Mx?=
OVCAR-5 NEnjPFlHfW6ldHnvckBCe3OjeR?= MUK1NEBvVQ>? NUm2PVg4UW6qaXLpeJMh[2WubDDtbYdz[XSrb36= NIj6UFgzOzN|NEOyOy=>
SKOV3ip2 MW\GeY5kfGmxbjDBd5NigQ>? MXm1NEBvVQ>? MXjJcohq[mm2czDj[YxtKG2rZ4LheIlwdg>? MojGNlM{OzR|Mke=
S462 M3Pke2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXSxNFAh|ryP M4HNOVczKGh? M3zEfWROW09? MmG5RZR1\W63YYTld{Bk\WyuIHfyc5d1cA>? MVSyN|MzQDFzNB?=
2884 M33nNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1[3W|ExOCEQvF2= MXu3NkBp NFHYdXlFVVOR NEnEOJVCfHSnboXheIV{KGOnbHyg[5Jwf3Sq M1fTcVI{OzJ6MUG0
2885 NUjLc5VpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHXh[3gyODBizszN M33BblczKGh? MXXEUXNQ MlvkRZR1\W63YYTld{Bk\WyuIHfyc5d1cA>? NGjleI0zOzN{OEGxOC=>
CRL-2396 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\Ob|ExOCEQvF2= M1zsNJdifGW{ NHfhbXFKSzVyPUCuNFkzKM7:TR?= M3zhXVI{OTV|NUK0
TIB-48 NID3S2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGXie48yODBizszN Mn;he4F1\XJ? MnfnTWM2OD1yLkC4PEDPxE1? NH\hZYozOzF3M{WyOC=>
CRL-2396 MVvDfZRwfG:6aXOgRZN{[Xl? MWixJO69VQ>? NY\EZYlMPDhiaB?= MUH3ZZRmeg>? MXfJcoR2[2W|IHHwc5B1d3Orcx?= NGjRSoEzOzF3M{WyOC=>
TIB-48 Ml\yR5l1d3SxeHnjJGF{e2G7 NHzLd3IyKM7:TR?= MY[0PEBp MWD3ZZRmeg>? M1\R[Wlv\HWlZYOgZZBweHSxc3nz NUGwOIhuOjNzNUO1NlQ>
AGS MnzHR5l1d3SxeHnjJGF{e2G7 NHiyUoExNjVizszN M4fXU|I1KGh? NH3yOZdFVVOR M4PaR2Rm[3KnYYPld{Bk\WyuIIP1dpZqfmGu NVHmV4p{OjJ7N{K2NVE>
FLO-1 MWDDfZRwfG:6aXOgRZN{[Xl? M13LUlAvPSEQvF2= NYjjT5Y2OjRiaB?= MmXZSG1UVw>? M1PaWGRm[3KnYYPld{Bk\WyuIIP1dpZqfmGu MW[yNlk4OjZzMR?=
OE33 MmDTR5l1d3SxeHnjJGF{e2G7 MorNNE42KM7:TR?= Mn7FNlQhcA>? NWLlbWVVTE2VTx?= MVPE[YNz\WG|ZYOgZ4VtdCC|dYL2bZZidA>? NXfwcplPOjJ7N{K2NVE>
SKLMS M{[1RmN6fG:2b4jpZ{BCe3OjeR?= MUC3OUBvVQ>? M3rKb|k3KGh? Mk\QTY5lfWOnczDhdI9xfG:|aYO= NUflPWR2OjJ6MkG5PVc>
Leio285 M1e5O2N6fG:2b4jpZ{BCe3OjeR?= NULhS5VJPzVibl2= M4CzWVk3KGh? M4DZN2lv\HWlZYOgZZBweHSxc3nz MXmyNlgzOTl7Nx?=
Mes-Sa NUnTN4M2S3m2b4TvfIlkKEG|c3H5 Mo[5O|Uhdk1? NEfw[XY6PiCq MkjaTY5lfWOnczDhdI9xfG:|aYO= NIDmdWszOjh{MUm5Oy=>
DAOY NGDoO5NEgXSxdH;4bYMhSXO|YYm= MmrONVAh|ryP NYjPdHdIPzJiaB?= MWLEUXNQ MnHZTWM2OD1yLkC0JO69VQ>? MYOyNlY3QTN|NR?=
IMR32 NWruRmpMS3m2b4TvfIlkKEG|c3H5 NXLjWpdPOTBizszN MWK3NkBp M4DkdmROW09? NEjZZWJKSzVyPUCuNFMh|ryP M1;zNlIzPjZ7M{O1
Molt-4 NHvvOG1EgXSxdH;4bYMhSXO|YYm= M1XTO|ExKM7:TR?= NIf2bG04OiCq NHvyNHJFVVOR NUKzN2o{UUN3ME2wMlAzKM7:TR?= MnPsNlI3Pjl|M{W=
MOLM-13 M3[xOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkjQN{DPxE1? NEXW[FA4OiCq NETHNZFFcW2rbnnzbIV{KGOnbHygeoli[mmuaYT5 Mki4NlI1QDh{NEm=
HL-60 NVm1dGF1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUnp[W83OyEQvF2= NXT2bXk3PzJiaB?= MYDEbY1qdmm|aHXzJINmdGxidnnhZoltcXS7 NEj6[oIzOjR6OEK0PS=>
MV4-11 NWG3NGttT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEKwVpY{KM7:TR?= MWG3NkBp MXvEbY1qdmm|aHXzJINmdGxidnnhZoltcXS7 M{HURlIzPDh6MkS5
SKM-1 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnTCN{DPxE1? NIHteYc4OiCq MmK5SIlucW6rc3jld{Bk\WyuII\pZYJqdGm2eR?= MUSyNlQ5QDJ2OR?=
SH2 M4m3O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYKzJO69VQ>? M3O2Z|czKGh? MWDEbY1qdmm|aHXzJINmdGxidnnhZoltcXS7 NVvnWI5oOjJ2OEiyOFk>
NOMO-1 NHrYd25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4ToWFMh|ryP MmnvO|IhcA>? M{PGeGRqdWmwaYPo[ZMh[2WubDD2bYFjcWyrdIm= MYCyNlQ5QDJ2OR?=
OCL-AML2 NIfTOo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlLxN{DPxE1? M3q5NlczKGh? NYCz[mxJTGmvaX7pd4hmeyClZXzsJJZq[WKrbHn0fS=> Mm\4NlI1QDh{NEm=
PL-21 NXu5SIJYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoPDN{DPxE1? NX:0OItOPzJiaB?= M1LabGRqdWmwaYPo[ZMh[2WubDD2bYFjcWyrdIm= MXyyNlQ5QDJ2OR?=
KG-1 NVz3SIZRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV[zJO69VQ>? NEXITmk4OiCq M2DJ[GRqdWmwaYPo[ZMh[2WubDD2bYFjcWyrdIm= MmK1NlI1QDh{NEm=
A172 NYnUOY4yS3m2b4TvfIlkKEG|c3H5 NWXibm9ZOTByIN88US=> MmC4NlQhcA>? NXzZZYVwTE2VTx?= NELIT|JKSzVyPUCuNVIxKM7:TR?= NUT6fo5pOjJ{N{SzPVk>
U87 M1G5WmN6fG:2b4jpZ{BCe3OjeR?= MoPwNVAxKM7:TR?= MkLRNlQhcA>? Mm[5SG1UVw>? MlHkTWM2OD1yLkGwOUDPxE1? MYWyNlI4PDN7OR?=
U251 MnzTR5l1d3SxeHnjJGF{e2G7 Mnj2NVAxKM7:TR?= MUCyOEBp NFv1c5RFVVOR Mm\ETWM2OD1yLkGwNEDPxE1? Ml3sNlIzPzR|OUm=
T98 NIDSNIZEgXSxdH;4bYMhSXO|YYm= NXLVfVZ3OTByIN88US=> NH3Q[WgzPCCq NVLUOGc1TE2VTx?= MnnDTWM2OD1yLkGyOUDPxE1? MlXaNlIzPzR|OUm=
LN18 NFzMWHdEgXSxdH;4bYMhSXO|YYm= NXjzUZNKOTByIN88US=> M2DBNlI1KGh? MWfEUXNQ NWCwWZdHUUN3ME2wMlIyOCEQvF2= Mm\aNlIzPzR|OUm=
LN443 NVjlbYNyS3m2b4TvfIlkKEG|c3H5 M4D0UFExOCEQvF2= MlPkNlQhcA>? Mmn1SG1UVw>? NE\EbGJKSzVyPUCuNlIxKM7:TR?= MmLENlIzPzR|OUm=
HF66 MUHDfZRwfG:6aXOgRZN{[Xl? M1joSlExOCEQvF2= NXvZeXQ2OjRiaB?= NICyRWlFVVOR M1O4eGlEPTB;MD6yNlUh|ryP NVnBSGNwOjJ{N{SzPVk>
HF2303 NWPPenVzS3m2b4TvfIlkKEG|c3H5 NY\CNm9POTByIN88US=> NYLPUHl2OjRiaB?= MXLEUXNQ MonnTWM2OD1yLkC2NEDPxE1? NUSzPGU6OjJ{N{SzPVk>
HF2359 Ml2wR5l1d3SxeHnjJGF{e2G7 NVnUXIRWOTByIN88US=> NWPn[WhTOjRiaB?= NVjVS3c2TE2VTx?= NIK4V|lKSzVyPUCuNFYxKM7:TR?= Mm\6NlIzPzR|OUm=
HF2414 MkDuR5l1d3SxeHnjJGF{e2G7 MYixNFAh|ryP MnH4NlQhcA>? MXjEUXNQ Ml7mTWM2OD1yLkC4NEDPxE1? NWnGcXpQOjJ{N{SzPVk>
A-673 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHnZNIEyOCEQvF2= MkC4PVYhcA>? NE\UfmpFVVOR NV7hd49IUUN3ME2wMlA{OiEQvF2= M{m5SVIyPDR6NUmx
TC-32 NXLRWGNOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzNfHcyOCEQvF2= MlLGPVYhcA>? MWTEUXNQ NIHvRY1KSzVyPUCuNFM6KM7:TR?= NH7FVXgzOTR2OEW5NS=>
TC-71 NUi0XWNjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmrmNVAh|ryP NGfC[Yk6PiCq NFjabIlFVVOR M1r4XmlEPTB;MD6xNFIh|ryP MlHSNlE1PDh3OUG=
SK-N-MC MljUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDDS|AyOCEQvF2= MVK5OkBp M3Ptc2ROW09? NInhOGVKSzVyPUCuNFczKM7:TR?= NGjPbpczOTR2OEW5NS=>
CHLA-9 MnHUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEnZepUyOCEQvF2= NHnHepE6PiCq MlqwSG1UVw>? MVnJR|UxRTBwMEG4JO69VQ>? NIryZ5kzOTR2OEW5NS=>
CHLA-10 M{\RbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYK5bmo4OTBizszN NHPXOJg6PiCq M1X0VmROW09? NVTne|BSUUN3ME2wMlA3OCEQvF2= NFPPUZIzOTR2OEW5NS=>
CHLA-25 NFXWSHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV:xNEDPxE1? MUG5OkBp M4TsWmROW09? NVPqOG9FUUN3ME2wMlE3QCEQvF2= NInifYUzOTR2OEW5NS=>
CHLA-32 M3qxXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\TZ3NKOTBizszN NXTndJVLQTZiaB?= M1;Ke2ROW09? NFPqUHRKSzVyPUCuNVM3KM7:TR?= NXT0S41UOjF2NEi1PVE>
CHLA-56 MoTuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX[xNEDPxE1? NW\KU5NvQTZiaB?= M3:5fGROW09? M{G0R2lEPTB;MUCg{txO NXTS[FlqOjF2NEi1PVE>
CHLA-258 Mn22S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVPPfIxEOTBizszN MYO5OkBp NI[xdlNFVVOR NV[w[4M2UUN3ME2wMlE{OiEQvF2= MkjDNlE1PDh3OUG=
COG-E-352 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXXGcmRWOTBizszN NG\M[lc6PiCq NGXNUIhFVVOR NVXmcmhlUUN3ME2wMlA1OyEQvF2= NGHjbWUzOTR2OEW5NS=>
CHLA-90 MkTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWSxNEDPxE1? M3[1Xlk3KGh? NH7Ue2lFVVOR NGKxc2VKSzVyPUCuNFYyKM7:TR?= MoXYNlE1PDh3OUG=
CHLA-119 MljMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk[wNVAh|ryP M3jYWVk3KGh? NWnPO3JnTE2VTx?= NYLUV3lFUUN3ME2wMlAzOiEQvF2= M3O1R|IyPDR6NUmx
CHLA-122 M{T2OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWqxNEDPxE1? NE\ZOlQ6PiCq NFzudo5FVVOR NWe2XIxVUUN3ME2wMlAyQSEQvF2= NV3jdoRkOjF2NEi1PVE>
CHLA-136 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYCxNEDPxE1? MXO5OkBp M3j6TGROW09? M1PhfmlEPTB;MD6wN|kh|ryP NXfmVFFVOjF2NEi1PVE>
CHLA-140 NWTLdoVzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEDOR4EyOCEQvF2= NFHw[2I6PiCq M{n2c2ROW09? MYrJR|UxRTBwMEK2JO69VQ>? NHzVNnczOTR2OEW5NS=>
LA-N-6 M1vLNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkDmNVAh|ryP M2P6clk3KGh? NG\4VndFVVOR MYTJR|UxRTBwMEW0JO69VQ>? MljiNlE1PDh3OUG=
NB-1643 NYfCR206T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3XUfVExKM7:TR?= NW[3XIhXQTZiaB?= NV;tU5MzTE2VTx?= NXHkdpgyUUN3ME2wMlA{PyEQvF2= Mo\6NlE1PDh3OUG=
NB-EBc1 NV;rPG9PT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MknVNVAh|ryP NIrr[YM6PiCq NFr1SFdFVVOR NWPrcVNuUUN3ME2wMlA2OCEQvF2= Ml7pNlE1PDh3OUG=
SK-N-BE-1 NYWzeHluT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGfpZVcyOCEQvF2= M3qwRVk3KGh? MVHEUXNQ NIGxTJhKSzVyPUCuNFI5KM7:TR?= M3\WcFIyPDR6NUmx
SK-N-BE-2 M{PxTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmCyNVAh|ryP NWTBNHVzQTZiaB?= MmDNSG1UVw>? MVzJR|UxRTBwMEO2JO69VQ>? MnHmNlE1PDh3OUG=
SMS-KAN NYnNWZkxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3W3TlExKM7:TR?= NGjjR5Q6PiCq NGrBPZFFVVOR M4f4T2lEPTB;MD6wN|Qh|ryP NXfCZVFoOjF2NEi1PVE>
SMS-KANR M2\SV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYnpUoExOTBizszN M3rnbVk3KGh? M{nZR2ROW09? NH3rOYVKSzVyPUCuNFI3KM7:TR?= NI\2bXgzOTR2OEW5NS=>
SMS-KCN NVzyVHFwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFPoOVUyOCEQvF2= M2jEW|k3KGh? M3K4Z2ROW09? M2HXTmlEPTB;MD6wNVkh|ryP MWCyNVQ1QDV7MR?=
SMS-KCNR M{HaUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGPWSlkyOCEQvF2= M1:0W|k3KGh? MlTUSG1UVw>? M3ewW2lEPTB;MD6wNVAh|ryP MXSyNVQ1QDV7MR?=
SMS-LHN NWnrUmpIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlXLNVAh|ryP NH3PUmU6PiCq MmjKSG1UVw>? MWHJR|UxRTBwMEOyJO69VQ>? NI\MO|QzOTR2OEW5NS=>
SMS-MSN M2Dve2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlXXNVAh|ryP MXy5OkBp M3uxTWROW09? NIfKTG1KSzVyPUCuNFIzKM7:TR?= Ml3KNlE1PDh3OUG=
SMS-SAN NHLPN2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3exelExKM7:TR?= M4nDdFk3KGh? MkTQSG1UVw>? MVzJR|UxRTBwMEKwJO69VQ>? MXyyNVQ1QDV7MR?=
Granta-4 NXjhXWZCS3m2b4TvfIlkKEG|c3H5 MmraNVAh|ryP MWO3JIQ> NHLLSJVKSzVyPUCuNFQxKM7:TR?= M3XFTlIyOjlzOE[3
DB MnPyR5l1d3SxeHnjJGF{e2G7 NH3MWHkyOCEQvF2= M33a[Fch\A>? NVHwTlh[UUN3ME2wMlA1OiEQvF2= NUXaRZd3OjF{OUG4Olc>
RL MULDfZRwfG:6aXOgRZN{[Xl? MVqxNEDPxE1? NHe1SVE4KGR? NVzCSmtGUUN3ME2wMlAyPSEQvF2= M{n1W|IyOjlzOE[3
K562 MkD4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3PuN|ExKM7:TR?= NV;DUGVKQTZiaB?= MVjJR|UxRTBwMEi3JO69VQ>? NYTIUm5yOjFyOUG2N|M>
LAMA-84 NHXVNIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVmxNEDPxE1? NUmyPWRDQTZiaB?= MWPJR|UxRTBwMEW3JO69VQ>? MnuzNlExQTF4M{O=
MM15 M2m5Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NInaXY01KM7:TR?= NEHFbJo4OiCq M17HSmROW09? NYf2blZ5UUN3ME2wMlE{KM7:TR?= MnvhNlA{QDJ6NES=
OPM1 M4\ybWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGHHS4s1KM7:TR?= NGOy[lk4OiCq NH7q[|VFVVOR NEHwOlRKSzVyPUCuNFMh|ryP NHTQNWwzODN6Mki0OC=>
RPM1 M3jQV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlXNOEDPxE1? NVnZb41sPzJiaB?= M4XKWmROW09? NVOwSWFWUUN3ME2xNE4{OiEQvF2= NUTUbHJCOjB|OEK4OFQ>
INA6 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYOzdVV1PCEQvF2= NVHmUoNYPzJiaB?= MUPEUXNQ NFjVbnJKSzVyPUCuNFAzKM7:TR?= NVvIN4VoOjB|OEK4OFQ>
OPM2 M2Hxb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYe0JO69VQ>? NEfoPXg4OiCq MYjEUXNQ NIK0U4FKSzVyPUSuN|ch|ryP M2jHcFIxOzh{OES0
MM1R Ml3vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonXOEDPxE1? MYG3NkBp NUDk[Y02TE2VTx?= MX7JR|UxRTFwNkig{txO MknFNlA{QDJ6NES=
DOX40 NWDpXpR{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlH3OEDPxE1? MnnhO|IhcA>? M4HrSmROW09? MnLPTWM2OD13LkS4JO69VQ>? MVOyNFM5Ojh2NB?=
LR5 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHPhNJk1KM7:TR?= MXW3NkBp MnPsSG1UVw>? NELEcVZKSzVyPUKuOVMh|ryP M3X5T|IxOzh{OES0
U266 MoPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVq0JO69VQ>? MmXDO|IhcA>? NW\5VFJCTE2VTx?= MV7JR|UxRTFwNEOg{txO NYe1[|lLOjB|OEK4OFQ>
RD NXHVS3g5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrUcpYyOCEQvF2= NV3jfY51QTZiaB?= MnziTWM2OD1yLkKyPEDPxE1? NUHHOVgzOjBzMEizN|g>
Rh41 M2LHWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYixNEDPxE1? M{DUeFk3KGh? M3j0V2lEPTB;MD6wPVAh|ryP M4fK[|IxOTB6M{O4
Rh30 M1\5PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV[0PHFMOTBizszN NH\vZlU6PiCq Mn3STWM2OD1yLkKzNEDPxE1? NXW5PINFOjBzMEizN|g>
BT-12 MkH0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVGxNEDPxE1? MV[5OkBp NEDQSlVKSzVyPUCuNFYxKM7:TR?= MWSyNFExQDN|OB?=
CHLA-266 NFGw[mhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{TqT|ExKM7:TR?= M2fJVlk3KGh? NYLxfFE4UUN3ME2wMlA4OiEQvF2= MojvNlAyODh|M{i=
TC-71 NHjYZnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVyxNEDPxE1? Mn7MPVYhcA>? NUTNTW56UUN3ME2wMlExOiEQvF2= NGjzd|QzODFyOEOzPC=>
SJ-GBM2 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXvPTpdZOTBizszN NH31XYg6PiCq NIP3d|JKSzVyPUCuNFUxKM7:TR?= MUeyNFExQDN|OB?=
NALM-6 M3X3UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWOxNEDPxE1? M3rEcVk3KGh? NYe4W|B[UUN3ME2wMlA3OiEQvF2= MUiyNFExQDN|OB?=
COG-LL-317 M2WzWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2f1Z|ExKM7:TR?= NV2wPFZmQTZiaB?= MkXwTWM2OD1yLkC0O{DPxE1? MX2yNFExQDN|OB?=
RS4-11 NVjLdpRrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEm1[I0yOCEQvF2= NFu1[oc6PiCq M2XTcmlEPTB;MD6wNVgh|ryP NE[yfXgzODFyOEOzPC=>
MOLT-4 NGDIUlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\wN|ExKM7:TR?= MV65OkBp M17oSWlEPTB;MD6wNlYh|ryP NH\YXpYzODFyOEOzPC=>
CCRF-CEM NFHFfFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnztNVAh|ryP MljSPVYhcA>? NI\JdldKSzVyPUCuNFk1KM7:TR?= MYCyNFExQDN|OB?=
Kasumi-1 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4TaSVExKM7:TR?= MUK5OkBp NGrsSHBKSzVyPUCuNVA{KM7:TR?= M3PGcVIxOTB6M{O4
Karpas-299 M1;zbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXTGWIJxOTBizszN NX3oVY9tQTZiaB?= M3jwSWlEPTB;MD6wN|gh|ryP Mn2yNlAyODh|M{i=
Ramos-RA1 Mmm0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXHBc|lEOTBizszN NV[wdXNrQTZiaB?= M{HWR2lEPTB;MD6xNlch|ryP M2nnSFIxOTB6M{O4

... Click to View More Cell Line Experimental Data

In vivo MLN8237 significantly reduces the tumor burden with tumor growth inhibition (TGI) of 42% and 80% at 15 mg/kg and 30 mg/kg, respectively, and prolongs the survival of mice compared with the control. [2]

Protocol

Kinase Assay
+ Expand

Aurora A radioactive Flashplate enzyme assay:

Aurora A radioactive Flashplate enzyme assay is conducted to determine the nature and degree of MLN8237-mediated inhibition in vitro. Recombinant Aurora A is expressed in Sf9 cells and purified with GST affinity chromatography. The peptide substrate for Aurora A is conjugated with biotin (Biotin-GLRRASLG). Aurora A kinase (5 nM) is assayed in 50 mM Hepes (pH 7.5), 10 mM MgCl2, 5 mM DTT, 0.05% Tween 20, 2 μM peptide substrate, 3.3 μCi/mL [γ-33P]ATP at 2 μM, and increasing concentrations of MLN8237 by using Image FlashPlates.
Cell Research
+ Expand
  • Cell lines: MM1.S, MM.1R, LR5, RPMI 8226, DOX40, OPM1, OPM2, INA6, and U266
  • Concentrations: Dissolved in DMSO, final concentrations ~10 μM
  • Incubation Time: 24, 48, and 72 hours
  • Method: Cells are exposed to various concentrations of MLN8237 for 24, 48, and 72 hours. Cells viability is measured using MTT assay, and cell proliferation is measured using 3[H]-thymidine incorporation. For cell cycle analysis, cells are permeabilized by 70% ethanol at -20 °C, and incubated with 50 μg/mL PI and 20 units/mL RNase-A. DNA content is analyzed by flow cytometry using BDFACS-Canto II and FlowJo software. For the detection of apoptosis and senescence, cells are stained with fluorescein isothiocyanate-annexin V and PI. Apoptotic cells are determined by flow cytometric analysis using BDFACS-Canto II and FlowJo software.
    (Only for Reference)
Animal Research
+ Expand
  • Animal Models: Severe combined immune-deficient (SCID) mice inoculated subcutaneously with MM1.S cells
  • Formulation: Formulated in 10% 2-hydroxypropyl-β-cyclodextrin/1% sodium bicarbonate
  • Dosages: ~30 mg/kg/day
  • Administration: Orally
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 27 mg/mL (52.03 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
In vivo 15% Captisol 30 mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 518.92
Formula

C27H20ClFN4O4

CAS No. 1028486-01-2
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02812056 Not yet recruiting Malignant Neoplasms of Digestive Organs|Malignant Neoplasms of Female Genital Organs|Malignant Neoplasms of Lip Oral Cavity and Pharynx|Malignant Neoplasms of Male Genital Organs M.D. Anderson Cancer Center|Millennium Pharmaceuticals, Inc. September 2016 Phase 1
NCT02700022 Recruiting Diffuse Large B-cell Lymphoma|Follicular Lymphoma|Burkitt Lymphoma UNC Lineberger Comprehensive Cancer Center|Millennium Pharmaceuticals, Inc. July 2016 Phase 1
NCT02719691 Recruiting Metastatic Breast Cancer|Solid Tumors University of Colorado, Denver May 2016 Phase 1
NCT02530619 Recruiting Acute Megakaryoblastic Leukemia|Myelofibrosis|Primary Myelofibrosis Northwestern University|The Leukemia and Lymphoma Society|Millennium Pharmaceuticals, Inc.|National Cancer Institute (NCI) October 2015 --
NCT02560025 Not yet recruiting Acute Myeloid Leukemia Massachusetts General Hospital|Takeda October 2015 Phase 2
NCT02551055 Recruiting Neoplasms, Advanced or Metastatic Millennium Pharmaceuticals, Inc. October 2015 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    What is the suggested formulation of this compound for mouse injection(i.p.)?

  • Answer:

    It can be dissolved in 6% DMSO/50% PEG 300/5% Tween 80/ddH2O at 10 mg/ml as a clear solution.

Aurora Kinase Signaling Pathway Map

Aurora Kinase Inhibitors with Unique Features

Related Aurora Kinase Products

Tags: buy Alisertib (MLN8237) | Alisertib (MLN8237) supplier | purchase Alisertib (MLN8237) | Alisertib (MLN8237) cost | Alisertib (MLN8237) manufacturer | order Alisertib (MLN8237) | Alisertib (MLN8237) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID